GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
August 23, 2023 09:00 ET
|
GRI Bio, Inc.
Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation...
Asthma Treatment Market Predicted to Reach USD 34.5 billion, Globally, by 2031 to Grow at a CAGR of 3.7% | Exclusive Report by Transparency Market Research Inc.
August 15, 2023 06:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global asthma treatment market is projected to flourish at a CAGR of 3.7% from 2022 to...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
July 24, 2023 09:00 ET
|
GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...
GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 15, 2023 08:45 ET
|
GRI Bio, Inc.
- Live webcast fireside chat on Thursday, June 22nd at 12:00 PM ET LA JOLLA, CA, June 15, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
May 08, 2023 16:05 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
March 16, 2023 16:24 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic...
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
March 14, 2023 16:01 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
February 27, 2023 16:05 ET
|
Adamis Pharmaceuticals Corporation
Combined company will have commercial products and a library of development candidates, two of which are clinical stageWill be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhDLead...
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
February 22, 2023 16:01 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
July 29, 2022 08:00 ET
|
Adamis Pharmaceuticals Corporation
ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on...